Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

707 - 3SBio

Next Previous
Drug Profile

707 - 3SBio

Alternative Names: 707; SSGJ-707

Latest Information Update: 27 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator 3SBio
  • Developer Sunshine Guojian Pharmaceutical
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Programmed cell death-1 ligand-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Endometrial cancer; Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 20 May 2025 Shenyang Sunshine Pharmaceutical plans a phase III trial for Non-small cell lung cancer (First-line therapy, Metastatic disease, Late-stage disease) in China (IV) (NCT06980272)
  • 10 Oct 2024 Phase-II clinical trials in Endometrial cancer (Late-stage disease, Combination therapy, Second-line therapy or greater) in China (Parenteral) (NCT06522828)
  • 10 Oct 2024 Phase-II clinical trials in Ovarian cancer (Late-stage disease, Combination therapy, Second-line therapy or greater) in China (Parenteral) (NCT06522828)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top